только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29. DOI: 10.3322/caac.21254.
  2. Soria F., Shariat S.F., Lerner S.P. et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35(3):379–87. DOI: 10.1007/s00345-016-1928-x.
  3. Margulis V., Shariat S.F., Matin S.F. et al. Outcomes of radical nephroureterectomy: А series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115(6):1224–33. DOI: 10.1002/cncr.24135.
  4. Shariat S.F., Favaretto R.L., Gupta A. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011;29(4):481–6. DOI: 10.1007/s00345-010-0594-7.
  5. Roupret M., Yates D.R., Comperat E., Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008;54(6):1226–36. DOI: 10.1016/j.eururo.2008.08.008.
  6. Acher P., Kiela G., Thomas K., O’Brien T. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010;106(3):300–2. DOI: 10.1111/j.1464-410X.2010.09443.x.
  7. Matin S.F., Coleman J.A. Misclassification of upper tract urothelial carcinoma in patients with Lynch syndrome. JAMA Oncol 2018;4(7):1010. DOI: 10.1001/jamaoncol.2018.0539.
  8. Therkildsen C., Eriksson P., Höglund M. et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 2018;12(8):1286–95. DOI: 10.1002/1878-0261.12325.
  9. Colin P., Koenig P., Ouzzane A. et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009;104(10):1436–40. DOI: 10.1111/j.1464-410X.2009.08838.x.
  10. Crivelli J.J., Xylinas E., Kluth L.A. et al. Effect of smoking on outcomes of urothelial carcinoma: А systematic review of the literature. Eur Urol 2014;65(4):742–54. DOI: 10.1016/j.eururo.2013.06.010.
  11. Cosyns J.P. Aristolochic acid and “Chinese herbs nephropathy”: А review of the evidence to date. Drug Saf 2003;26(1):33–48. DOI: 10.2165/00002018-200326010-00004.
  12. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54(1):1–7. DOI: 10.1002/em.21756.
  13. Rosenquist T.A., Grollman A.P. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst) 2016;44:205–11. DOI: 10.1016/j.dnarep.2016.05.027.
  14. Jelakovic B., Karanović S., Vuković-Lela I. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81(6):559–67. DOI: 10.1038/ki.2011.371.
  15. Chen C.H., Dickman K.G., Moriya M. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 2012;109(21):8241–6. DOI: 10.1073/pnas.1119920109.
  16. Nortier J.L., Martinez M.C., Schmeiser H.H. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342(23):1686–92. DOI: 10.1056/NEJM200006083422301.
  17. Babjuk M., Burger M., Compérat E.M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ). Eur Urol 2019;76(5):639–57. DOI: 10.1016/j.eururo.2019.08.016.
  18. Siegel R.L., Miller K.D., Jemal А. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. DOI: 10.3322/caac.21387.
  19. Munoz J.J., Ellison L.M. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000;164(5):1523–5.
  20. Cosentino M., Palou J., Gaya J.M. et al. Upper urinary tract urothelial cell carcinoma: Location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013;31(1):141–5. DOI: 10.1007/s00345-012-0877-2.
  21. Xylinas E., Rink M., Margulis V. et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 2012;61(5):1069–70. DOI: 10.1016/j.eururo.2012.02.042.
  22. Li W.M., Shen J.-T., Li C.-C. et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010;57(6):963–9. DOI: 10.1016/j.eururo.2009.12.032.
  23. Inman B.A., Tran V.-T., Fradet Y., Lacombe L. Carcinoma of the upper urinary tract: Predictors of survival and competing causes of mortality. Cancer 2009;115(13):2853–62. DOI: 10.1002/cncr.24339.
  24. Cowan N.C. CT urography for hematuria. Nat Rev Urol 2012;9(4):218–26. DOI: 10.1038/nrurol.2012.32.
  25. Rouprêt M., Babjuk M., Burger M. et al. Upper urinary tract urothelial cell carcinoma. European Association of Urology guidelines. Доступно по: https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/ (дата обращения: 17.02.2022).
  26. Ito Y., Kikuchi E., Tanaka N. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011;185(5):1621–6. DOI: 10.1016/j.juro.2010.12.035.
  27. Raman J.D., Shariat S.F., Karakiewicz P.I. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011; 29(6):716–23. DOI: 10.1016/j.urolonc.2009.11.007.
  28. The Paris System for Reporting Urinary Cytology. Eds.: E.M. Wojcik, D.F.I. Kurtycz, D.L. Rosenthal. Switzerland: Springer Nature Switzerland AG, 2022.
  29. Chen A.A., Grasso М. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol 2008;22(6):1371–4. DOI: 10.1089/end.2008.0096.
  30. Johannes, J.R., Nelson Е., Bibbo М., Bagley D.H. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol 2010;184(3):879–82. DOI: 10.1016/j.juro.2010.05.023.
  31. Sudakoff G.S., Dunn D.P., Guralnick M.L. et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008;179(3):862–7. DOI: 10.1016/j.juro.2007.10.061.
  32. Wang, L.J., Wong Y.-C., Chuang C.-K. et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol 2009;181(2):524–31. DOI: 10.1016/j.juro.2008.10.024.
  33. Wang L.J., Wong Y.-C., Huang C.-C. et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol 2010;183:48–55. DOI: 10.1016/j.juro.2009.08.144.
  34. Jinzaki M., Matsumoto K., Kikuchi E. et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol 2011;196(5):1102–9. DOI: 10.2214/AJR.10.5249.
  35. Hurel S., Rouprêt M., Seisen T. et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol 2015;33(3):335–41. DOI: 10.1007/s00345-014-1311-8.
  36. Verhoest G., Shariat S.F., Chromecki T.F. et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol 2011;29(4):495–501. DOI: 10.1007/s00345-011-0710-3.
  37. David R.A., James B., Adeloye D. et al. Accuracy of ultrasound vs computed tomography scan for upper urinary tract malignancies and development of a risk-based diagnostic algorithm for haematuria in a UK tertiary centre. Int Urol Nephrol 2021 Jan;53(1):49–57. DOI: 10.1007/s11255-020-02615-7.
  38. Dana A., Hélénon O. Urinary tract imaging: conventional radiology and ultrasound. J Radiol 2004;85(2 Pt 2):159–68. (In Fr.). DOI: 10.1016/s0221-0363(04)97564-6.
  39. Takahashi N., Glockner J.F., Hartman R.P. et al. Gadolinium enhanced magnetic resonance urography forupper urinary tract malignancy. J Urol 2010;183(4):1330–65. DOI: 10.1016/j.juro.2009.12.031.
  40. Lee K.S., Zeikus E., DeWolf W.C. et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol 2010;65(3):185–92. DOI: 10.1016/j.crad.2009.11.003.
  41. Walton T.J., Novara G., Matsumoto K. et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011;108(3):406–12. DOI: 10.1111/j.1464-410X.2010.09826.x.
  42. Marchioni M., Primiceri G., Cindolo L. et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: А systematic review and meta-analysis. BJU Int 2017;120(3):313–9. DOI: 10.1111/bju.13935.
  43. Guo R.Q., Hong P., Xiong G.-Y. et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: А meta-analysis. BJU Int 2018;121(2):184–93. DOI: 10.1111/bju.14053.
  44. Bus M.T., de Bruin D.M., Faber D.J. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015;29(2):113–23. DOI: 10.1089/end.2014.0551.
  45. Brien J.C., Shariat S.F., Herman M.P. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010;184(1):69–73. DOI: 10.1016/j.juro.2010.03.030.
  46. Abouassaly R., Alibhai S.M.H., Shah N. et al. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010;76(4):895–901. DOI: 10.1016/j.urology.2010.04.020.
  47. Kata S.G., Aboumarzouk O.M., Zreik A. et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther 2016;13:255–60. DOI: 10.1016/j.pdpdt.2015.08.002.
  48. Lindner A.K., Schachtner G., Tulchiner G. et al. Lynch syndrome: its impact on urothelial carcinoma. Int J Mol Sci 2021;22(2):531. DOI: 10.3390/ijms22020531.
  49. Mikhaylenko D.S., Tanas A.S., Zaletaev D.V., Nemtsova M.V. Application areas of traditional molecular genetic methods and NGS in relation to hereditary urological cancer diagnosis. J Oncol 2020;7363102. DOI: 10.1155/2020/7363102.
  50. Seisen T., Peyronnet B., Dominguez-Escrig J.L. et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70(6):1052–68. DOI: 10.1016/j.eururo.2016.07.014.
  51. O’Brien T., Ray E., Singh R. et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60(4):703–10. DOI: 10.1016/j.eururo.2011.05.064.
  52. Cutress, M.L., Stewart G.D., Zakikhani P. et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012;110(5):614–28. DOI: 10.1111/j.1464-410X.2012.11068.x.
  53. Seisen T., Granger B., Colin P. et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015;67(6):1122–33. DOI: 10.1016/j.eururo.2014.11.035.
  54. Cornu J.N., Rouprêt M., Carpentier X. et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010;28(2):151–6. DOI: 10.1007/s00345-009-0494-x.
  55. Roupret M., Traxer О., Tligui М. et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 2007;51(3):709–13; discussion 714. DOI: 10.1016/j.eururo.2006.07.019.
  56. Ni S., Tao W., Chen Q. et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012;61(6):1142–53. DOI: 10.1016/j.eururo.2012.02.019.
  57. Ariane M.M., Colin Р., Ouzzane А. et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012;19(1):301–8. DOI: 10.1245/s10434-011-1841-x.
  58. Simone G., Papalia R., Guaglianone S. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol 2009;56(3):520–6. DOI: 10.1016/j.eururo.2009.06.013.
  59. Adibi M., Youssef R., Shariat S.F. et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012;19(12):1060–6. DOI: 10.1111/j.1442-2042.2012.03110.x.
  60. Clements M.B., Krupski Т.L., Culp S.H. Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis. Ann Surg Oncol 2018;25(9):2550–62. DOI: 10.1245/s10434-018-6557-8.
  61. Rodriguez J.F., Packiam V.T., Boysen W.R. et al. Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol 2017;31(7):661–5. DOI: 10.1089/end.2017.0086.
  62. Aboumohamed A.A., Krane L.S., Hemal A.K. et al. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015;194(6):1561–6. DOI: 10.1016/j.juro.2015.07.081.
  63. Fajkovic H., Cha E.K., Jeldres C. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol 2012;187(3):845–51. DOI: 10.1016/j.juro.2011.10.158.
  64. Roscigno M., Brausi M., Heidenreich A. et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60(4):776–83. DOI: 10.1016/j.eururo.2011.07.009.
  65. Lughezzani G., Jeldres C., Isbarn H. et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010;75(1):118–24. DOI: 10.1016/j.urology.2009.07.1296.
  66. Moschini M., Foerster B., Abufaraj М. et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017;35(10):1541–7. DOI: 10.1007/s00345-017-2026-4.
  67. Dominguez-Escrig J.L., Peyronnet В., Seisen Т. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder cancer. Eur Urol Focus 2019:5(2):224–41. DOI: 10.1016/j.euf.2017.09.015.
  68. Kondo T., Hashimoto Y., Kobayashi H. et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. Int J Urol 2010;17(10):848–54. DOI: 10.1111/j.1442-2042.2010.02610.x.
  69. Mori K. et al. Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis //The Journal of Urology. – 2020. – Т. 203. – №. 6. – С. 1075-1084.
  70. Jeldres C., Lughezzani G., Sun M. et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010;183(4):1324–9. DOI: 10.1016/j.juro.2009.12.018.
  71. Colin P., Ouzzane A., Pignot G. et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012;110(8):1134–41. DOI: 10.1111/j.1464-410X.2012.10960.x.
  72. Lopez-Beltran A., Sauter G., Gasser T. et al. Tumours of the urinary system. In: World Health Organization classification of tumors: pathology and genetics of tumours of the urinary system and male genital organs. Eds.: J.N. Eble, G. Sauter, J. Epstein, I. Sesterhenn. Lyon: IARC Press, 2004.
  73. Song Y.S., Cho J.S., Cho K.S. et al. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: A comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract. Urol Int 2010;85(1):47–51. DOI:10.1159/000296294.
  74. Irie A., Iwamura M., Kadowaki K. et al. Intravesical instillation of bacille Calmette–Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 2002;59(1):53–7. DOI: 10.1016/s0090-4295(01)01488-1.
  75. Horiguchi H., Yoneyama T., Hatakeyama S. et al. Impact of bacillus Calmette–Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol 2018;35(4):41. DOI: 10.1007/s12032-018-1102-y.
  76. Tomisaki I. Т. Kubo, Minato А., Fujimoto N. Efficacy and tolerability of bacillus Calmette–Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest 2018;36(2):152–7. DOI: 10.1080/07357907.2018.1430815.
  77. Yossepowitch O., Lifshitz D.A., Dekel Y. et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005;173(3):890–3. DOI: 10.1097/01.ju.0000147747.89028.64.
  78. Giannarini G., Kessler Т.M., Birkhäuser F.D. et al. Antegrade perfusion with bacillus Calmette–Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: Who may benefit? Eur Urol 2011;60(5):955–60. DOI: 10.1016/j.eururo.2011.07.051.
  79. Ito A., Shintaku I., Satoh M. et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31(11):1422–7. DOI: 10.1200/JCO.2012.45.2128.
  80. Miyamoto K., Ito A., Wakabayashi M. et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III). Jpn J Clin Oncol 2018;48(1):94–7. DOI: 10.1093/jjco/hyx158.
  81. Fang D., Li X.S., Xiong G.Y. et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: А systematic review and meta-analysis. Urol Int 2013;91(3):291–6. DOI: 10.1159/000350508.
  82. Foerster B., D’Andrea D., Abufaraj M. et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol 2019;37(7):430–6. DOI: 10.1016/j.urolonc.2019.02.004.
  83. Leow J.J., Martin-Doyle W., Fay A.P. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66(3):529–41. DOI: 10.1016/j.eururo.2014.03.003.
  84. Matin S.F., Margulis V., Kamat А. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116(13):3127–34. DOI: 10.1002/cncr.25050.
  85. Liao R.S., Gupta М., Schwen Z.R. et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 2018;200(1):68–73. DOI: 10.1016/j.juro.2017.12.054.
  86. Porten S., Siefker-Radtke А.O., Xiao L. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120(12):1794–9. DOI: 10.1002/cncr.28655.
  87. Kubota Y., Hatakeyama S., Tanaka Т. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: А multicenter study. Oncotarget 2017;8(60):101500–8. DOI: 10.18632/oncotarget.21551.
  88. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998;16(3):1099–102. DOI: 10.1200/JCO.1998.16.3.1099.
  89. Goldberg H., Klaassen Z., Chandrasekar T. et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget 2018;9(27):18797–810. DOI: 10.18632/oncotarget.24694.
  90. Necchi A., Vullo S.L., Mariani L. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2018;121(2):252–9. DOI: 10.1111/bju.14020.
  91. Fujita K., Taneishi K., Inamoto T. et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 2017;17(1):110. DOI: 10.1186/s12894-017-0305-4.
  92. Birtle A.J., Chester J.D., Jones R.J. et al. Results of POUT: A phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018;36(6 Suppl):407. DOI: 10.1200/JCO.2018.36.6_suppl.407.
  93. D.F. Bajorin, Witjes J.A., Gschwend J.E. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384(22):2102–14. DOI: 10.1056/NEJMoa2034442.
  94. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. Доступно по: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma (дата обращения: 17.02.2022).
  95. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): А multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI: 10.1016/S1470-2045(17)30065-7.
  96. Czito B., Zietman А., Kaufman D. et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004;172(4 Pt 1):1271–5. DOI: 10.1097/01.ju.0000137910.38441.8a.
  97. Iwata T., Kimura S., Abufaraj M. et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol 2019;37(10):659–71. DOI: 10.1016/j.urolonc.2019.05.021.
  98. Faltas B.M., Gennarelli R.L., Elkin E. et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol 2018;36(1):9.e11–17. DOI: 10.1016/j.urolonc.2017.09.009.
  99. Приказ от 10 мая 2017 г. № 203н Минздрава России «Об утверждении критериев оценки качества медицинской помощи». Доступно по: https://docs.cntd.ru/document/436733768 (дата обращения: 17.02.2022).
  100. Bellmunt J., de Wit R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur J Cancer 2001;37(17), 2212–5. DOI:10.1016/s0959-8049(01)00295-7.
  101. Bamias A., Aravantinos G., Deliveliotis C. et al. Docetaxel and cisplatin with granulocyte colonystimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22(2):220–8. DOI: 10.1200/JCO.2004.02.152.
  102. Choueiri T.К., Jacobus S., Bellmunt J. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32(18):1889–94. DOI: 10.1200/JCO.2013.52.4785.
  103. Culine S., Theodore C., De Santis M. et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94(10):1395–401. DOI: 10.1038/sj.bjc.6603118.
  104. Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: А single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. DOI: 10.1016/S0140-6736(16)32455-2.
  105. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683.
  106. Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial cancer. N Engl J Med 2020;383(13):1218–30. DOI: 10.1056/NEJMoa2002788.
  107. Sternberg C.N., de Mulder P.H., Schornagel J.H. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19(10):2638–46. DOI: 10.1200/JCO.2001.19.10.2638.
  108. Пембролизумаб. Инструкция к лекарственному препарату. ЛП-003972, 2021.
  109. von der Maase Н., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI: 10.1200/JCO.2000.18.17.3068.
  110. Balar A.V., Castellano D., O’Donnell P.H. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): А multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483–92. DOI: 10.1016/S1470-2045(17)30616-2.
  111. Атезолизумаб. Инструкция к лекарственному препарату. ЛП-004652-030620. Изм. № 1 к ЛП-004652-030620.
  112. De Santis M., Bellmunt J., Meadet G. et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II – results of EORTC study 30986. J Clin Oncol 2009;27(33):5634–9. DOI:10.1200/JCO.2008.21.4924.
  113. Powles T., Park S.H., Voog E. et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020;38(18 Suppl):LBA1. DOI: 10.1200/JCO.2020.38.18_suppl.LBA1.
  114. Galsky M.D., Arija J.A.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395(10236):Р1547–57. DOI: 10.1016/S0140-6736(20)30230-0.
  115. Moore M.J., Tannock I.F., Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15(12):3441–5. DOI: 10.1200/JCO.1997.15.12.3441.
  116. Albers P., Siener R., Härtlein M. et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma – prognostic factors for response and improvement of quality of life. Onkologie 2002;25(1):47–52. DOI: 10.1159/000055202.
  117. Sharma P., Callahan M.K., Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17(11):1590–8. DOI: 10.1016/S1470-2045(16)30496-X.
  118. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: А single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031):1909–20. DOI: 10.1016/S0140-6736(16)00561-4.
  119. Powles T., Durán I., van der Heijden М.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018;391(10122):748–57. DOI: 10.1016/S0140-6736(17)33297-X.
  120. Sternberg C.N., Loriot Y., James N. et al. Primary results from SAUL, a multinational ingle-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019;76(1):73–81. DOI: 10.1016/j.eururo.2019.03.015.
  121. Нahn A.W., Giri S., Pathak R. et al. Effect of adjuvant radiotherapy on survival in patients with locoregional urothelial malignancies of the upper urinary tract. Anticancer Res 2016;36(8):4051–5. 
  122. Huang Y.C., Chang Y.-H., Chiu K.-H. et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep 2016;6:38175. DOI: 10.1038/srep38175.
  123. Владимирова Л.Ю., Гладков О.А., Когония Л.М. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):502–11. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-35.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-502-511.
  124. Манзюк Л.В., Багрова С.Г., Копп М.В. и др.  Использование остеомодифицирующих агентов для профилактики и лечения патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):512–20. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-36.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-512-520.
  125. Сакаева Д.Д., Орлова Р.В., Шабаева М.М. Лечение инфекционных осложнений фебрильной нейтропении и назначение колониестимулирующих факторов. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):521–30. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-37.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-521-530.
  126. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):531–44. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-38.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-531-544.
  127. Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):545–63. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-39.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-545-563.
  128. Королева И.А., Болотина Л.В., Гладков О.А. и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию». Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):564–74. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-40.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-564-574.
  129. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):591–603. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-44.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-591-603.
  130. Сомонова О.В., Антух Э.А., Елизарова А.Л. и др. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):604–9. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-45.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-604-609.
  131. Буйденок Ю.В. Рекомендации по лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):610–6. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-46.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-610-616.
  132. Проценко С.А., Антимоник Н.Ю., Берштейн Л.М. и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):636–65. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-48.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-636-665.
  133. Сытов А.В., Лейдерман И.Н., Ломидзе С.В. и др. Практические рекомендации по нутритивной поддержке онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8(3):575–83. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-41.pdf (дата обращения: 17.02.2022). DOI: 10.18027/2224-5057-2018-8-3s2-575-583.
  134. Ploussard G., Xylinas Е., Lotan Y. et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015;67(4):803–12. DOI: 10.1016/j.eururo.2014.08.003.
  135. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005–2017). PM R. 2017;9(9 S2):S347–84. DOI: 10.1016/j.pmrj.2017.07.074.
  136. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: А systematic review. Sports Med 2014;44(9):1289–304. DOI: 10.1007/s40279-014-0207-5.
  137. Lee M.J., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012;30(15 Suppl):9019. DOI:10.1200/jco.2012.30.15_suppl.9019.
  138. Rick O., von Hehn U., Mikus Е. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase – III study. Bioelectromagnetics 2017;38(2):85–94. DOI: 10.1002/bem.22005.
  139. Kılınç M., Livanelioğlu A., Yıldırım S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014;46(5):454–60. DOI: 10.2340/16501977-1271.
  140. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: А systematic review and meta-analysis. PLoS One 2014;9(9):e107418. DOI: 10.1371/journal.pone.0107418.
  141. Ross M., Cartlidge F.E. Scalp cooling: A literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017;21(2):226–33. DOI: 10.1188/17.CJON.226-233.
  142. Avci P., Gupta G.K., Clark J. et al. Low-level laser (light) therapy (LLLT) fortreatment of hair loss. Lasers Surg Med 2014;46(2):144–51. DOI: 10.1002/lsm.22170.
  143. Visser W.S., Te Riele W.W., Boerma D. et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: А systematic review. Ann Coloproctol 2014;30(3):109–14. DOI: 10.3393/ac.2014.30.3.109.
  144. Shigeta K., Kikuchi E., Hagiwara M. et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017;198(6):1278–85. DOI: 10.1016/j.juro.2017.06.073.
  145. Matsumoto K., Novara G., Gupta A. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: An international study. BJU Int 2011;108(8 Pt 2):E304–9. DOI: 10.1111/j.1464-410X.2011.10188.x.
  146. Singla N., Fang D., Su X. et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017;197(5):1208–13. DOI: 10.1016/j.juro.2016.11.094.
  147. Simsir A., Sarsik B., Cureklibatir I. et al. Prognostic factors for upper urinary tract urothelial carcinomas: Stage, grade, and smoking status. Int Urol Nephrol 2011;43(4):1039–45. DOI: 10.1007/s11255-011-9915-z.
  148. Rink M., Xylinas E., Margulis V. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013;63(6):1082–90. DOI: 10.1016/j.eururo.2012.06.029.
  149. Sundi D., Svatek R.S., Margulis V. et al. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 2012;30(3):266–72. DOI: 10.1016/j.urolonc.2010.04.002.
  150. Gadzinski A.J., Roberts W.W., Faerber G.J., Wolf J.S. Jr. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012;26(5):566–73. DOI: 10.1089/end.2011.0220.
  151. Lee J.N., Kwon S.Y., Choi G.-S. et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014;110(4):468–75. DOI: 10.1002/jso.23589.
  152. Waldert M., Karakiewicz P.I., Raman J.D. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105(6):812–7. DOI: 10.1111/j.1464-410X.2009.08821.x.
  153. Favaretto R.L., Bahadori A., Mathieu R. et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol 2017;35(1):113–20. DOI: 10.1007/s00345-016-1835-1.
  154. Scarpini S., Rouprêt M., Renard-Penna R. et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012;30(2):182–7. DOI: 10.1016/j.urolonc.2009.12.003.
  155. Roupret M., Fromont G., Azzouzi A.-R. et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005;65(6):1233–7. DOI: 10.1016/j.urology.2005.01.019.
  156. Krabbe L.M., Heitplatz B., Preuss S. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol 2017;198(6):1253–62. DOI: 10.1016/j.juro.2017.06.086.
  157. Афонин С.В. Современная диагностика и лечение уротелиального рака верхних мочевых путей. Дисс. ...канд. мед. наук. М. – 2010.
  158. Stellato, M.; Santini, D.; Cursano, M.C.; Foderaro, S.; Tonini, G.; Procopio, G. Bone metastases from urothelial carcinoma. The dark side of the moon. J. Bone Oncol. 2021, 31, 100405.
  159. O"Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015 Aug 28;7(8):202-11. doi: 10.4329/wjr.v7.i8.202. PMID: 26339464; PMCID: PMC4553252.
  160. Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017 Feb 1;19(2):162-174.
  161. Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.NEngl J Med, 2017. 376: 1015.
  162. Sideris S. et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer //Molecular and Clinical Oncology. – 2016. – Т. 4. – №. 6. – С. 1063-1067.
  163. Powles T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018;391:748.
  164. Galsky M. D. The role of taxanes in the management of bladder cancer //The oncologist. – 2005. – Т. 10. – №. 10. – С. 792-798.
  165. McCaffrey J. A. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma //Journal of Clinical Oncology. – 1997. – Т. 15. – №. 5. – С. 1853-1857.
  166. Lorusso V, Pollera CF, Temi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34:1208-1212, 1998
  167. Stadler WM, Kuzer T, Roth B, et al: A phase II trial of single agent gemcitabine in previously untreated patients ith metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997.
  168. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced  urothelial cancer. J Clin Oncol 15:3441-3445, 1997.
  169. Bellmunt J. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 //Journal of Clinical Oncology. – 2012. – Т. 30. – №. 10. – С. 1107.
  170. Arriola A. G. P. et al. PD-L1 expression reveals significant association with squamous differentiation in upper tract urothelial carcinoma //American Journal of Clinical Pathology. – 2019. – Т. 151. – №. 6. – С. 561-573.
  171. Miyama Y. et al. The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count //Cancer medicine. – 2018. – Т. 7. – №. 9. – С. 4330-4338.
  172. Morrissey K. M. et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting //Cancer chemotherapy and pharmacology. – 2019. – Т. 84. – №. 6. – С. 1257-1267.
  173. O"Brien T. et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial) //European urology. – 2011. – Т. 60. – №. 4. – С. 703-710.
  174. van Doeveren T. et al. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial //Contemporary Clinical Trials Communications. – 2018. – Т. 9. – С. 121-129.
  175. Moriarty M. A. et al. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy //BMC urology. – 2015. – Т. 15. – С. 1-6.

Для продолжения работы требуется вход / регистрация